Usefulness of CDK5RAP3, CCNB2, and RAGE genes for the diagnosis of lung adenocarcinoma

International Journal of Biological Markers

Volumn 22, Issue 2, 2007, Pages 108-113

  Stav, David ^a   Bar, I ^a   Sandbank, J ^a  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

CCNB2; CDK5RAP3; Expression microarray; Lung adenocarcinoma; RAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; CYCLIN B2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 5 REGULATORY SUBUNIT ASSOCIATED PROTEIN 3; ENZYME ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BRONCHOSCOPY; CANCER DIAGNOSIS; CANCER STAGING; CELL CYCLE PROGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG SURGERY; MALE; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

EID: 34447301769     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.3142     Document Type: Article

References (18)

1. Fry WA, Phillips JL, Menck H. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999; 86: 1867-76.
2. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
3. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
4. Hofmann HS, Hansen G, Burdach S, Bartling B, Silber RE, Simm S. Discrimination of human lung neoplasm from normal lung by two target genes. Am J Respir Crit Care Med 2004; 170: 516-9.
5. Jiang H, Luo S, Li H. CDK5 activator binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. J Biol Chem 2005; 270: 1-9.
6. Roberts JM. Evolving ideas about cyclins. Cell 1999; 98: 129-32.
7. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-5004.
8. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-712.
9. Schenk S, Schraml P, Bendik I, Ludwig CU. A novel polymorphism in the promoter of the RAGE gene is associated with non-small cell lung cancer. Lung Cancer 2001; 32: 7-12.
10. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. Histological typing of lung and pleural tumors, 3rd ed. Berlin: Springer-Verlag 1999; 31-47.
11. Huber JP. Robust statistical procedures, CBMS-NSF Regional Conference Series in Applied Mathematics, Society for Industrial and Applied Mathematics 1977; 25-27.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995; 52: 289-300.
13. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-75.
14. Yekutieli D, Benjamini Y. Resampling-based false discovery rate controlling multiple test procedures for correlated test statistics. J Stat Plan Infer 1999; 82: 171-96.
15. Applied Biosystems. Relative quantitation of gene expression. ABI PRISM 7700 Sequence Detection System. In: User Bulletin No. 2. Foster City, CA: PE Applied Biosystems, 1997.
16. Au NH, Cheang M, Huntsman DG, et al Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004; 204: 101-9.
17. Manes T, Zheng DQ, Tognin S, Woodard AS, Marchisio PC, Languino LR. Alpha(v)beta3 integrin expression up-regulates cdc2, which modulates cell migration. J Cell Biol 2003; 161: 817-26.
18. Gordon GJ, Jensen RV, Hsiao LL, et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003; 95: 598-605.